DelveInsight’s “Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Axial Spondyloarthritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Axial Spondyloarthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Axial Spondyloarthritis: An Overview
Axial spondyloarthritis (axSpA) is an umbrella term for inflammatory arthritis type that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS).
Up to 6% of people with chronic back pain will ultimately receive a diagnosis of axial spondyloarthritis. However, the disease often takes as long as 10 years to be diagnosed—a delay that can hugely impact your quality of life and lead to disability, missed time at work, and increased healthcare costs. Unfortunately, awareness of axial spondyloarthritis, including symptoms and what it takes to get diagnosed, is severely lacking.
Axial Spondyloarthritis Market Key Facts
-
Depending on geographic area, study population or data source, case definition, and ascertainment methods, recent studies have reported the prevalence of Axial Spondyloarthritis to range from 9/10,000 to 30/10,000 in the general population.
-
It is observed that around 5.5 million Americans have Axial Spondyloarthritis (axSpA), an inflammatory form of arthritis associated with chronic lower back pain. It generally starts in people during their teens, twenties, or maybe in their thirties.
-
As per DelveInsight, males and females are equally affected in case of Axial spondyloarthritis.
-
The current average delay to diagnosis from when symptoms start is 8.5 years, by which irreversible damage to the spine may have occurred. Also, 59% of people with axial SpA (AS) report experiencing mental health problems than 25% of those with musculoskeletal conditions overall.
Axial Spondyloarthritis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Axial Spondyloarthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Axial Spondyloarthritis market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Axial Spondyloarthritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Epidemiology Segmentation
-
Total Prevalent cases of Spondyloarthritis
-
Total Prevalent cases of Axial Spondyloarthritis
-
Age-specific cases of Axial Spondyloarthritis
-
Type-specific cases of Axial Spondyloarthritis
Axial Spondyloarthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis market or expected to get launched during the study period. The analysis covers Axial Spondyloarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Axial Spondyloarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market
Axial Spondyloarthritis Therapeutics Analysis
Companies worldwide are persistently working towards developing new treatment therapies for Axial Spondyloarthritis. The launch of the emerging therapies is expected to improve the treatment scenario in the coming years.
Some of the key companies in the Axial Spondyloarthritis market at the global level include:
-
FunPep Co Ltd
-
UCB Biopharma
-
Mycenax Biotech
-
Kinevant Sciences
-
Qyuns Therapeutics
-
Izana Bioscience
-
Clover Biopharmaceuticals
-
Suzhou Zelgen Biopharmaceuticals
And many others.
Axial Spondyloarthritis Therapies covered in the report include:
-
FPP003
-
KIN-1901
-
QX 002N
-
Namilumab
-
Jaktinib
-
Bimekizumab:
-
SCB-808
-
ENIA11
And many others
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Axial Spondyloarthritis Competitive Intelligence Analysis
4. Axial Spondyloarthritis Market Overview at a Glance
5. Axial Spondyloarthritis Disease Background and Overview
6. Axial Spondyloarthritis Patient Journey
7. Axial Spondyloarthritis Epidemiology and Patient Population
8. Axial Spondyloarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Axial Spondyloarthritis Unmet Needs
10. Key Endpoints of Axial Spondyloarthritis Treatment
11. Axial Spondyloarthritis Marketed Products
12. Axial Spondyloarthritis Emerging Therapies
13. Axial Spondyloarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Axial Spondyloarthritis Market Outlook (7 major markets)
16. Axial Spondyloarthritis Access and Reimbursement Overview
17. KOL Views on the Axial Spondyloarthritis Market.
18. Axial Spondyloarthritis Market Drivers
19. Axial Spondyloarthritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Healthcare Reports by DelveInsight
Orthopedic Trauma Devices Market
“Orthopedic Trauma Devices Market” Research Report provides comprehensive insights into the historical and forecasted Orthopedic Trauma Devices Market size, share, trends, and growth estimation. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market